September 9, 2021 | 10:00AM EDT | 2:00PM UTC | 4:00PM CEST
Despite significant advances in drug development tools, technologies and strategies in recent years, these advances have not translated into successful treatments for brain diseases. While obstacles like the blood-brain barrier do pose additional challenges in this field, more can, and needs to be done to drive progress towards thus far elusive therapeutic successes.
We desperately need new approaches to innovate the landscape of drug discovery in brain therapeutics, and interestingly, the COVID-19 pandemic has yielded some critical insights. In the last year, the COVID-19 pandemic has provided us a new window into how to think and work differently to smash old timelines for drug discovery.
Through this virtual event, we invite the global drug discovery community in brain therapeutics to come together to brainstorm about lessons learned from these pandemic times, and how to apply these new strategies to catalyze success in our own field. In particular, we will address new models for collaboration and integration of multi-stakeholder partnerships to re-envision a more efficient and effective ecosystem of drug discovery for CNS therapeutics.
Key Topics:
This ePanel event continues the conversations initiated during a roundtable discussion at the Keystone Symposia on Brain Therapeutics: Disruptive Technologies and Opportunities, on February 16-19, 2020 in Santa Fe. We have invited the panelists to reconvene now in light of the new landscape shaped by COVID-19.
#VKSBrainTherapy22
Mabel Loza
University of Santiago de Compostela
Jim Audia
Chicago Biomedical Consortium
Maria-Jesus Blanco
Sage Therapeutics
Julija Hmeljak
Company of Biologists
Chas Bountra
University of Oxford
Sohini Chowdhury
Michael J. Fox Foundation
Kalpana Merchant
Vincere Biosciences, Inc.
The views expressed in this ePanel are those of the participants and not necessarily of the participants’ organizations or of Keystone Symposia.